Skip to content

Study · Non-randomized trial · n = 11 · 2023

4 results

Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects.

Yamane T, Imai M, Bamba T, Uchiyama S

Clinical nutrition ESPEN5 May 2023Cited by 14 (Europe PMC)

PMID37344088 (opens in a new tab)DOI10.1016/j.clnesp.2023.04.031 (opens in a new tab)PepBankPUB-37344088
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

IntroductionNicotinamide adenine dinucleotide (NAD+) is a coenzyme of the NAD+-dependent protein deacetylase sirtuin-1 (SIRT1). An increase in NAD+ concentration induces SIRT1 activation that results in various health benefits. Since nicotinamide mononucleotide (NMN) is a precursor of NAD+, NMN ingestion is expected to have multiple health benefits such as alleviation of aging, lifestyle-related and neurodegenerative diseases, through the activation of SIRT1. In this study, we aimed to determine the effects of daily NMN ingestion on plasma levels of NMN and NAD+.MethodsHealthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly. Physiological and laboratory tests were performed within 2 h after lunch (at 2 pm) before and during NMN administration.ResultsOral administration of NMN increased the plasma concentrations of NMN and NAD+, and the postprandial serum insulin levels. The elevation levels of NMN and insulin varied widely among individuals. No adverse symptoms were observed in the participants.ConclusionsOral administration of NMN elevates plasma levels of NMN and NAD+, and postprandial serum insulin levels.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, oral NMN increased plasma NMN concentrations.

    In plain wordsIn healthy volunteers, oral NMN increased plasma NMN levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePlasma NMN
    Study

    n = 11

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    250 mg once daily · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Oral administration of NMN increased the plasma concentrations of NMN and NAD+, and the postprandial serum insulin levels.
    1 context sentence
    Summary · context
    Healthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly.
  2. 02HumanNon-randomized trialMechanism

    In healthy volunteers, oral NMN increased plasma NAD+ concentrations.

    In plain wordsIn healthy volunteers, oral NMN increased plasma NAD+ levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePlasma NAD+
    Study

    n = 11

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    250 mg once daily · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Oral administration of NMN increased the plasma concentrations of NMN and NAD+, and the postprandial serum insulin levels.
    1 context sentence
    Summary · context
    Healthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly.
  3. 03HumanNon-randomized trialMechanism

    In healthy volunteers, oral NMN increased postprandial serum insulin levels.

    In plain wordsIn healthy volunteers, oral NMN increased insulin levels after meals.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePostprandial serum insulin
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    250 mg once daily · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Oral administration of NMN increased the plasma concentrations of NMN and NAD+, and the postprandial serum insulin levels.
    1 context sentence
    Summary · context
    Healthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly.
  4. 04HumanNon-randomized trialSafety outcome

    In healthy volunteers receiving NMN, no adverse symptoms were observed.

    In plain wordsIn healthy volunteers receiving NMN, no adverse symptoms were observed.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableAdverse symptoms
    Study

    n = 11

    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg once daily · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse symptoms were observed in the participants.
    1 context sentence
    Summary · context
    Healthy volunteers received 250 mg of NMN once a day in the morning (n = 11) for 12 weeks, and the plasma concentrations of NMN and NAD+ were measured monthly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.